Research programme: antisense therapeutics - Ionis Pharmaceuticals/Genuity Science
Latest Information Update: 20 Aug 2021
At a glance
- Originator Ionis Pharmaceuticals
- Class Antisense elements
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Unspecified